4.5 Article

Prognostic implications of hypoxia-inducible factor-la in epidermal growth factor receptor-negative non-small cell lung cancer

Journal

LUNG CANCER
Volume 72, Issue 1, Pages 100-107

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2010.08.005

Keywords

Non-small cell lung cancer; Hypoxia-inducible factor; Epidermal growth factor receptor

Funding

  1. Gachon University Biomedical Research Institute

Ask authors/readers for more resources

Hypoxia-inducible factor (HIF)1 alpha is a regulatory subunit of HIF-1 that is stabilized and activated under hypoxic conditions. In non-small cell lung cancer (NSCLC), over-expression of HIF-1 alpha. has been associated with poor overall survival. However, there is conflicting data on the role of HIF1 alpha as a prognostic factor. Some studies have demonstrated close association between the HIF1 alpha signal pathways and epidermal growth factor receptors (EGFRs). We evaluated the prognostic significance of HIF-1 alpha expression in 178 NSCLC patients using tissue microarray in the context of EGFR gene copy number and protein expression status. EGFR gene copy number was evaluated using fluorescent in situ hybridization (FISH), and EGFR protein expression was determined using immunohistochemistry (IHC). The difference in overall survival (OS) between HIF-1 alpha-positive and HIF-1 alpha-negative groups was statistically significant in patients with low EGFR gene copy number and negative EGFR expression (log-rank test, P=0.03). In univariate and multivariate analyses, HIF1 alpha was a significant worse prognostic factor for OS in patients with low EGFR gene copy number and negative EGFR expression (hazard ratio = 2.992; 95% Cl, 1.113-8.045; P=0.03 in univariate analysis and hazard ratio = 8.127; 95% Cl, 1.874-35.251; P< 0.01 in multivariate analysis). The results demonstrated that the prognostic significance of HIF-1 a should be validated in the context of EGFR status in NSCLC patients, and the gene and protein status of EGFR and HIF-1 a will be important to help select patients most likely to derive the greatest clinical benefit from EGFR or HIF-1 alpha targeted therapies. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available